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Edited by Jesus AvilaAbstract The physiological role of the prion protein is largely
unknown. Here, clustering of prion at the surface of GT1-7 cells
was observed upon anti-prion antibody treatments. This cluster-
ing was associated with a rapid and transient phosphorylation of
the mitogen activated protein kinases (MAPKs) extracellular
receptor kinases 1 and 2 (ERK1/2), and also of the microtubule-
destabilizing protein stathmin at serine 16. The speciﬁcity of this
antibody-mediated activation was ascertained by its inhibition by
prion small interfering RNA. The phosphorylation of ERK1/2
but not that of stathmin was abolished by the MAPK/ERK
kinase 1 inhibitor U0126, whereas both signaling pathways were
blocked by the speciﬁc inhibitor of the epidermal growth factor
receptor AG1478, suggesting the likely recruitment of this
receptor upon prion clustering.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The causing agent of the transmissible spongiform en-
cephalopathies is thought to be a protein called PrPsc which
represents an abnormally conformed ‘scrapie’ isoform of the
cellular prion protein (PrPc) [1]. PrPc is a ubiquitous gly-
coprotein highly expressed in neurons, mostly anchored at
the cell surface via a C-terminal glycosylphosphatidylinositol
(GPI) moiety. Mice devoid of PrPc (PrP=) develop nor-
mally and are resistant to scrapie inoculation [2] but, like
conditional post-natal knockout mice [3], showed no major
phenotype that could unravel a clear physiological function
of PrPc. The best described property of PrPc is its high af-* Corresponding author. Fax: +33-1-45-87-61-32.
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doi:10.1016/j.febslet.2004.08.076ﬁnity for Cu(II), which suggests that PrPc could participate
in copper metabolism and protection against oxidative stress
[4]. Indeed, primary cultures of neurons from PrP= mice
exhibit increased susceptibility to oxidative stress [5]. PrPc
has also been proposed to be involved in neurite outgrowth
and neuronal survival in cell cultures of primary neurons [6].
Moreover, PrPc localization in ‘lipid rafts’ is compatible
with roles in cell adhesion and/or transmembrane signaling
[7]. Consistent with these hypotheses, several cellular part-
ners of PrPc have been proposed, including the extracellular
matrix protein laminin, laminin receptors and the neural cell
adhesion molecule (NCAM) [8,9], but to date there is no
functional ligand of PrPc which has been clearly identiﬁed
and widely accepted. Therefore, antibody cross-linking has
been used to identify PrPc induced signaling pathways in
diﬀerentiated murine 1C11 neuronal cells, revealing a cave-
olin-dependent coupling of PrPc to the tyrosine kinase Fyn
[10]. Recently, the same group also showed the production
of NADPH oxidase-dependent reactive oxygen species
(ROS) and the phosphorylation of extracellular receptor
kinases 1 and 2 (ERK1/2) in 1C11, in GT1-7 neurohypo-
thalamic and BW5147 lymphoid cells [11]. These results
suggest a function of PrPc in cell-redox homeostasis through
ROS production. In addition, PrPc antibody-mediated cross-
linking in vivo was lately found to trigger rapid and ex-
tensive apoptosis in hippocampal and cerebellar neurons,
further arguing for PrPc functions in the control of neuronal
survival [12]. The physiological relevance of PrPc antibody
cross-linking remains to be demonstrated but these studies
strongly support a role of PrPc in the transduction of in-
tracellular signaling pathways. As it is a GPI-anchored
protein, PrPc very likely associates with a transmembrane
protein to transduce signals.
In this study, we searched for intracellular targets acti-
vated after PrPc antibody-mediated cross-linking in GT1-7
neurohypothalamic cells. In particular, we studied the
phosphorylation of stathmin, a tubulin-binding protein reg-
ulated by phosphorylation at four serine residues by several
protein kinases [13–15]. Treatment of GT1-7 cells with the
anti-prion SAF34 and SAF61 monoclonal antibodies (mAbs)
resulted in clustering of PrPc at the cell surface as well as in
the induction of at least two independent signaling path-
ways. Our results suggest that PrPc activation might be
coupled with the control of microtubule dynamics, but also
that the transmembrane tyrosine kinase EGF receptor could
be a functional partner of PrPc.blished by Elsevier B.V. All rights reserved.
Fig. 1. PrPc immunoﬂuorescence staining on control GT1-7 cells (left),
or after treatment in culture with the SAF34 or SAF61 mAbs (10 lg/
ml) for 10 min (right) (see Section 2). PrPc immunolocalization was
revealed with Alexa 546-conjugated goat anti-mouse immunoglobu-
lins. Images were acquired and processed using the same protocol with
a confocal microscope and represent a projection of stacks. Bar: 10
lm.
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2.1. Cell culture and small interfering RNA transfection
Mouse GT1-7 cells [16] were grown at 37 C, 5.5% CO2, in Dul-
becco’s modiﬁed Eagle’s medium with 4.5 g/l glucose (DMEM, Life
Technologies, Cergy-Pontoise, France) supplemented with 10% v/v
fetal bovine serum (FBS, Life Technologies) and antibiotics (100 IU/ml
penicillin and 100 lg/ml streptomycin, Life Technologies). For small
interfering RNA (siRNA) transfection, cells were plated at 6 104
cells/cm2 and transfected 24 h after plating with the Lipofectamine
2000 reagent according to the manufacturer’s instructions (Invitrogen,
Cergy-Pontoise, France). Brieﬂy, 2 ll Lipofectamine 2000 was mixed
with siRNAs in 100 ll of Opti-MEM medium and, after 30 min at
room temperature, was added to the cells without antibiotics. Anti-
body treatments were performed 48 h after transfection on serum-de-
prived cells. PrPc siRNA used for prion silencing and the scramble
dsRNA sequence used as a control were as in [17] and were synthesized
by Proligo (Paris, France).
2.2. Antibody treatments and cell lysis
Cells were grown in 12-well plates and, at 60–70% conﬂuence, were
serum starved for 18 h before treatment with puriﬁed mouse anti-PrPc
mAbs SAF34, SAF61 [18] or anti-HA-Tag mAb 12CA5 [19] at 10 lg/
ml in the presence of 0.1% bovine serum albumin (BSA cell culture
tested, Sigma, St. Quentin, France) for 10 min at 37 C. Control cells
were treated with BSA alone. When indicated, cells were incubated
with inhibitors (U0126, 10 lM, Cell signaling technology, or AG1478,
100 nM, Calbiochem) for 20 min at 37 C prior to antibody treatment.
After treatment, the culture medium was removed and the cells were
washed twice with ice-cold phosphate-buﬀered saline (PBS) before
being lysed in 100 ll loading buﬀer (50 mM Tris–HCl, pH 6.8, 2%
SDS, 10% glycerol, 1% b-mercaptoethanol, bromophenol blue).
2.3. Electrophoresis and immunoblot analysis
Samples diluted in loading buﬀer were heated for 5 min at 95 C and
loaded onto a 13% SDS–PAGE gel. Electrotransfer and immunoblot
analysis were performed as described previously [20]. The primary
antibodies used were the following: mouse monoclonal anti-P-ERK1/2
(clone mitogen activated protein kinase (MAPK)-YT, Sigma), rabbit
anti-ERK1/2 (Upstate), mouse monoclonal anti-PrPc SAF83 [20] and
rabbit anti-phosphostathmin at serine 16 [14]. Immunoblots were de-
veloped using the ECL kit (Amersham) and quantiﬁcation was per-
formed with the SCION software (Scion Corporation). All
experiments were repeated three times independently and statistical
analyses were performed using Student’s t tests: * corresponds to
P < 0:05.
2.4. Immunoﬂuorescence
GT1-7 cells were grown on glass coverslips coated with poly-D,L-
ornithin (0.75 lg/cm2, Sigma, St. Louis, MO). After antibody treat-
ments for 10 min, the cells were washed with cold PBS and ﬁxed at 4 C
for 30 min with 2% formaldehyde/30 mM sucrose and for 20 min in
methanol. Cells were washed in PBS and blocked for 1 h with 3% BSA
(fraction V, PAA, Linz, Austria). Control cells were incubated after
ﬁxation with puriﬁed anti-PrPc mAb SAF34 or SAF61 (10 lg/ml) for 1
h at room temperature and washed with PBS. PrPc immunolocaliza-
tion was revealed with alexaﬂuor 546-conjugated goat anti-mouse
immunoglobulins (Molecular Probes Europe, Leiden, Holland) incu-
bated for 1 h at room temperature. After extensive washes, the slides
were mounted in mowiol 4-88 (Calbiochem, La Jolla, CA) and ob-
served under a confocal microscope (TCS, Leica) set on sequential
mode with 200 nm optical sections. Images were analyzed with the
MetaMorph software (Universal Imaging).3. Results
3.1. Anti-prion antibody treatment induces clustering of PrPc at
the surface of GT1-7 cells
We ﬁrst analyzed by immunoﬂuorescence the eﬀect of PrPc
antibody-mediated cross-linking on its distribution at the cell
surface of GT1-7 cells which, as we showed previously, express
high levels of endogenous PrPc [20]. We used two mousemonoclonal anti-prion antibodies, SAF34, directed against the
ﬂexible octarepeat region of PrPc (amino acids 59–89), and
SAF61, recognizing PrPc residues 144–152. Serum-deprived
GT1-7 cells were treated in culture with the relevant mAb (at
10 lg/ml for 10 min), then ﬁxed without permeabilization, and
PrPc localization was revealed with ﬂuorescent secondary an-
tibodies. The immunostaining speciﬁcity of the anti-PrPc an-
tibodies was veriﬁed on primary cortical neuron cultures from
PrP= mice, where they revealed no staining (not shown).
Immunoﬂuorescence after anti-PrPc antibody treatments of
GT1-7 cells revealed the formation of small clusters of PrPc at
the surface of the cells, which were not detected on non-treated
control cells immunostained with the same mAbs after ﬁxation
(Fig. 1). These results show that the SAF34 and SAF61 mAbs
induce a clustering of PrPc at the surface of GT1-7 cells. We
thus further used these mAbs and, in particular, SAF34, which
had not been used for such studies before, to characterize the
eﬀect of anti-PrPc treatment on intracellular signaling in GT1-
7 cells.
3.2. PrPc siRNA knockdown inhibits anti-PrPc antibody induced
activation of ERK1/2
We assessed the speciﬁcity of the responses of GT1-7 cells to
anti-PrPc antibody treatments by inhibiting the expression of
the PrPc protein with PrPc speciﬁc siRNA transfection
(Fig. 2). The expression of PrPc was followed by Western blot
analysis revealing the typical, highly glycosylated isoforms
pattern described in GT1-7 cells [20]. We used previously de-
scribed siRNA duplexes speciﬁc for mouse PrPc (PrPc siRNA),
as well as scrambled double stranded RNA (dsRNA) unrelated
Fig. 2. (A) Dose-dependent siRNA silencing of PrPc: anti-PrPc im-
munoblot with the SAF83 mAb, 48 h after transfection of GT1-7 cells
with various concentrations of PrPc siRNA, compared to control
dsRNA (C). (B) Cells transfected with either control dsRNA or PrPc
siRNA duplexes were treated for 10 min without mAb ()) or with (+)
the SAF34 mAb (10 lg/ml). ERK1/2 phosphorylation was revealed
with anti-P-ERK1/2 antibodies and total ERK was used as a loading
control of the gel. Quantiﬁcation shows an increase of P-ERK1/2 in
cells transfected with the control dsRNA and treated with the SAF34
mAb and no activation when the cells are transfected with PrPc siR-
NA. Quantiﬁcation and statistical analyses were performed on three
independent experiments (*P < 0.05).
Fig. 3. Serum deprived GT1-7 cells were treated for 10 min without
mAb ()) or with (+) the SAF34 mAb (10 lg/ml). When indicated, the
MKK1 inhibitor U0126 (10 lM) or the EGFR inhibitor AG1478 (100
nM) was added to the cells 20 min prior to antibody treatment. (A)
Immunoblot analyses of phosphorylation of ERK1/2 and stathmin at
serine 16. (B) Quantiﬁcation of the immunoblots for P-ERK1/2 and
stathmin P-16. Total ERK1/2 was used as a loading control of the gel.
j No inhibitor (NI), U0126 (U, 10 lM) and  AG1478 (AG, 100
nM). Quantiﬁcation and statistical analyses were performed on three
independent experiments (*P < 0.05).
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cells transfected with PrPc siRNA displayed a dose-dependent
inhibition of PrPc expression, as compared to control dsRNA
transfected cells (Fig. 2A). The most eﬀective concentration of
siRNA tested (500 nM) yielded a 70–80% PrPc depletion and
was used to examine the eﬀects of anti-PrPc treatments on such
PrPc depleted GT1-7 cells. On cells transfected with control
dsRNA, immunoblots revealed that treatment with the SAF34
mAb (at 10 lg/ml for 10 min) induced, as expected [11], the
phosphorylation of ERK1/2 (Fig. 2B). A 2-fold increase in
ERK1/2 phosphorylation was observed in these transfected
cells (Fig. 2B), whereas a nearly 5-fold activation was observed
in non-transfected cells (see below and Fig. 3), probably re-
ﬂecting a side eﬀect of the membrane-destabilizing transfection
protocol. This activation of ERK1/2 was totally abolished in
cells treated with PrPc siRNA (Fig. 2B), thus demonstrating
the PrPc speciﬁcity of the signaling pathway induced bySAF34. Similar results were observed also with the SAF61
anti-PrPc mAb (not shown).
3.3. Anti-PrPc antibody treatment induces rapid and transient
phosphorylation of ERK1/2 and stathmin
The increase of phospho-ERK1/2 (P-ERK1/2) detected by
immunoblot in response to treatment of GT1-7 cells with the
SAF34 mAb was rapid, with a peak at 10 min (Fig. 3), and
transient, as no residual activation was detected after 45 min
(not shown). As a further control, we used an isotypic unre-
lated IgG2a mAb (clone 12CA5) which did not induce acti-
vation of ERK1/2 (not shown).
In addition to its 5-fold eﬀect on ERK1/2 phosphorylation,
the SAF34 mAb also induced the phosphorylation of stathmin
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rabbit polyclonal antibody (Fig. 3A). The phosphorylation of
stathmin followed the same time course as P-ERK1/2 but its
induction was relatively less pronounced, slightly higher than
2-fold (Fig. 3B). Stathmin can be phosphorylated at four res-
idues but serine 16 was the only residue where we detected an
increased phosphorylation after anti-PrPc antibody treatment.
This phosphorylation is known to inhibit the microtubule
destabilizing activity of stathmin [21,22].
Treatment of the cells with the compound U0126 (10 lM), a
speciﬁc inhibitor of MAPK kinase 1 (MKK1), prior to acti-
vation with the SAF34 mAb, completely blocked the phos-
phorylation of ERK1/2 (Fig. 3A). The basal level of ERK1/2
was strongly inhibited by the U0126 compound, but no acti-
vation was detected even after longer exposure of the immu-
noblot. This result conﬁrms previous observations with
PD98059 [11], another speciﬁc inhibitor of MKK1/2, showing
that MKK1/2 mediates the activation of ERK1/2 upon anti-
PrPc treatment. In contrast, the phosphorylation of stathmin is
completely independent of the MKK/ERK pathway as the
inhibitor U0126 had no eﬀect on its induction by SAF34
(Fig. 3A and B).
Because the phosphorylation of stathmin serine 16 is
known to be induced by epidermal growth factor (EGF)
[21], we used tyrphostin AG1478 (100 nM), a speciﬁc in-
hibitor of the EGF receptor (EGFR), to examine its po-
tential involvement in response to anti-PrPc treatments. In
basal conditions, AG1478 slightly decreased the level of P-
ERK1/2 and increased the phosphorylation of stathmin at
serine 16 (Fig. 3A, lane 5 compared to lane 1). On the
other hand, AG1478 completely blocked the phosphoryla-
tion of stathmin at serine 16 induced by the SAF34 mAb
and also strongly inhibited the activation of ERK1/2
(Fig. 3A, lane 6 and 3B). The inhibition of P-ERK1/2 was
not complete, leaving about 15% of residual phosphoryla-
tion, which indicates that there could be a partly indepen-
dent pathway involved in the activation of ERK. These
results suggest that the EGFR plays an essential role in the
signaling induced by anti-PrPc antibodies in GT1-7 cells.
We observed similar results, albeit with less pronounced
eﬀects, with the SAF61 mAb in all experiments performed,
indicating that both antibodies have similar eﬀects.4. Discussion
In this study, we show that PrPc cross-linking with speciﬁc
antibodies results in clustering of PrPc at the surface of GT1-7
neurohypothalamic cells. This clustering is associated with a
rapid and transient phosphorylation of the MAP kinases
ERK1/2 and stathmin at serine 16. This antibody-mediated
activation is speciﬁc of PrPc as it is fully inhibited by PrPc
siRNA. The phosphorylation of ERK1/2 but not that of
stathmin was abolished by the MKK1 inhibitor U0126, show-
ing that the treatments with the anti-PrPc SAF34 and SAF61
mAbs induce at least two independent signaling pathways.
Unexpectedly, in the same conditions as for GT1-7 cells, the
SAF34 and SAF61 mAbs failed to induce these signaling
pathways in primary embryonic neuron cultures (from cortex
or hippocampus) or in rat neuroblastoma B104 cells (not
shown). We have previously shown that GT1-7 cells highlyexpress hyperglycosylated forms of PrPc as compared to B104
cells and primary cultures [20]. It is therefore possible that the
glycosylation state of PrPc inﬂuences its interaction with
functional partners responsible for the coupling of PrPc with
signaling pathways. Comparison of these diﬀerent cell models
should allow to identify the molecular determinants at the
basis of the diﬀerences observed in terms of signaling pathways
induced by anti-PrPc antibodies.
Interestingly, using immunoﬂuorescence studies, we re-
vealed that antibody treatments in GT1-7 cells induce the
formation of PrPc clusters by an unknown mechanism.
Because mAbs have bivalent binding properties, they are
able to induce dimerization. We can hypothesize that PrPc
dimerization could activate signaling pathways and result in
further clustering of the protein. Clustering could therefore
be regarded as a sign of PrPc activation. In addition, we
observed that this antibody-mediated PrPc clustering induces
the activation of ERK1/2, consistent with what was recently
described by others [11].
We also identiﬁed stathmin as a novel intracellular target
phosphorylated in response to this antibody treatment.
Stathmin is a cytosolic tubulin-binding protein that can be
phosphorylated on up to four serine residues, serine 16, 25, 38
and 63, in response to the activation of various intracellular
signaling pathways, in particular when triggered by extracel-
lular signals [15]. Stathmin binds tubulin heterodimers and has
a microtubule-destabilizing activity downregulated by phos-
phorylation [23]. Although serine 25 is mainly activated by
ERK1/2 [24], we could not detect signiﬁcant phosphorylation
of this serine despite the strong activation of the ERK1/2
pathway in our experiments. In contrast, we observed phos-
phorylation of stathmin serine 16 independently of ERK1/2.
The phosphorylation at serine 16 is essential for regulating the
microtubule-destabilizing activity of stathmin [22]. Our data
thus suggest a possible coupling of PrPc with the dynamics of
microtubules via the stathmin protein.
Because the phosphorylation of stathmin on serine 16 is
known to be induced upon activation of the EGFR [21,25], it
was of interest to test its potential implication. We observed
that both signaling pathways were totally or mostly blocked by
the speciﬁc tyrphostin AG1478 EGFR inhibitor, suggesting a
recruitment and transactivation of this receptor upon anti-
body-mediated PrPc clustering. Interestingly, it is now well
established that the EGFR can be transactivated, by auto-
phosphorylation in the absence of EGF, in response to various
stimuli, for instance through the activation of the G protein-
coupled receptors (GPCRs), engagement of adhesion mole-
cules or after cholesterol depletion [26–28]. Therefore, it is
possible that clustering of PrPc at the cell surface, as observed
by immunoﬂuorescence staining, could locally recruit and ac-
tivate a fraction of EGFR. The MAPK pathway could be in-
duced following transactivation of the EGFR. Nevertheless,
the EGFR inhibitor did not completely abolish the activation
of ERK1/2, which could be attributed to the activation of
another intracellular signaling pathway independent of the
EGFR. Recently, the production of ROS in response to anti-
PrPc antibody has been described in 1C11 and GT1-7 cells [11].
In relation with these ﬁndings, it has been reported that the
EGFR can induce the generation of ROS, participating in cell
survival and proliferation [29]. Altogether, these results argue
for a role of PrPc in normal cell homeostasis, possibly via
transactivation of the EGFR.
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